EP Patent

EP1040831A2 — Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death

Assigned to Pfizer Products Inc · Expires 2000-10-04 · 26y expired

What this patent protects

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

USPTO Abstract

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

Drugs covered by this patent

Patent Metadata

Patent number
EP1040831A2
Jurisdiction
EP
Classification
—
Expires
2000-10-04
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.